Search

Your search keyword '"Renzo, Colombo"' showing total 4 results
Start Over Author "Renzo, Colombo" Publisher elsevier
4 results on '"Renzo, Colombo"'

1. Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): A Randomised Controlled Study

Author

Juan Palou Redorta, Francesco Sanguedolce, Gemma Sancho Pardo, Martin Romancik, Gianni Vittori, Andrea Minervini, Fabrizio Di Maida, Richard Lunik, Renzo Colombo, Vincenzo Serretta, Bülent Çetinel, Vittorio Bini, Davide Corradengo, and Massimo Lazzeri

Subjects
Prostate cancer, Radiotherapy, Cystitis, Hyaluronic acid, Chondroitin sulfate, Questionnaries, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Radiation-induced cystitis is a common side effect of radiotherapy (RT) to the pelvic area. Hyaluronic acid (HA) and chondroitin sulfate (CS) are components of the urothelial mucosa and positive results have been obtained for intravesical HA/CS instillations for the treatment of urinary tract infections and bladder pain syndrome. HA/CS may also have a protective effect against RT bladder toxicity. Objective: To investigate whether HA and CS protect the urothelium during RT, alleviate lower urinary tract symptoms, and improve quality of life. Design, setting, and participants: This multicentre randomised controlled trial was conducted across seven centres in four countries. Male patients aged ≥18 yr scheduled to undergo primary intensity-modulated radiotherapy for localised prostate cancer were enrolled. Intervention: Patients were randomised to intravesical HA/CS plus an oral formulation of curcumin, quercetin, HA, and CS (group A) or no treatment (group B). Outcome measurements and statistical analysis: The primary endpoint was absolute changes from baseline to follow-up in urinary domain scores for the Expanded Prostate Cancer Index Composite (EPIC), the International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), and the EuroQol Group EQ-5D-5L questionnaire. Data analysis for efficacy and safety outcomes was performed using an intention-to-treat (ITT) approach; the ITT population was defined as all randomised patients. Results and limitations: Of 57 patients screened, 49 were enrolled and randomly assigned to either active treatment (group A, n = 25) or the control (group B, n = 24). Three patients in the control group withdrew after randomisation. Changes from baseline to 12 mo were worse in the control group for subtotal scores for urinary symptoms and impact of symptoms on quality of life and for the total score (p = 0.05, p = 0.003, and p = 0.008, respectively). There was a significant time × group interaction in favour of active treatment for the incontinence symptom score (p = 0.011) and bother score (p = 0.017). The absence of a sham procedure and/or placebo is the main limitation. Conclusions: Our results suggest that intravesical HA/CS in combination with an oral formulation may reduce urinary symptoms and improve QoL at short-term (1 yr) follow-up. Patient summary: We investigated whether hyaluronic acid (HA) and chondroitin sulfate (CS) have a protective effect against the bladder toxicity of radiotherapy for prostate cancer. HA/CS used for weekly bladder irrigation for 6 wk and given orally with curcumin and quercetin for 12 wk reduced urinary incontinence symptoms and bother measured at 1-year follow-up. This may hold promise as a preventive treatment if the results are confirmed in further trials.

Published
2021
Full Text
View/download PDF

2. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle -invasive Bladder Cancer

Author

Marco Bianchi, Alberto Briganti, Ewan A. Gibb, Joep J. de Jong, Maurizio Colecchia, Ryan Dittamore, Elena Farè, Andrea Gallina, Andrea Salonia, Joost L. Boormans, Andrea Necchi, Jeffrey S. Ross, Francesco Montorsi, Peter C. Black, Filippo Pederzoli, Yang Liu, Renzo Colombo, Laura Marandino, Umberto Capitanio, Nicola Fossati, Roberta Lucianò, Patrizia Giannatempo, Elai Davicioni, Giorgio Gandaglia, Marco Bandini, Daniele Raggi, Urology, Necchi, A., Raggi, D., Gallina, A., Ross, J. S., Fare, E., Giannatempo, P., Marandino, L., Colecchia, M., Luciano, R., Bianchi, M., Colombo, R., Salonia, A., Gandaglia, G., Fossati, N., Bandini, M., Pederzoli, F., Capitanio, U., Montorsi, F., de Jong, J. J., Dittamore, R., Liu, Y., Davicioni, E., Boormans, J. L., Briganti, A., Black, P. C., and Gibb, E. A.

Subjects
Male, Oncology, medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Cystectomy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Internal medicine, Gene signature, medicine, Humans, Neoplasm Invasiveness, Neoadjuvant therapy, Aged, Retrospective Studies, Chemotherapy, Bladder cancer, business.industry, Gene Expression Profiling, Biomarker, Immunotherapy, Middle Aged, medicine.disease, Neoadjuvant Therapy, Progression-Free Survival, Treatment Outcome, Urinary Bladder Neoplasms, Neoadjuvant immunotherapy, 030220 oncology & carcinogenesis, T-stage, Female, business, Muscle-invasive bladder cancer
Abstract

Background: The PURE-01 study (NCT02736266) evaluated the use of pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective: To evaluate the ability of molecular signatures to predict the pathological complete response (CR: ypT0N0) and progression-free survival (PFS) after pembrolizumab and RC. Design, setting, and participants: We analyzed the expression data from patients with T2–4aN0M0 MIBC enrolled in the PURE-01 study (N = 84) and from patients of a retrospective multicenter cohort treated with cisplatin-based neoadjuvant chemotherapy (NAC; N = 140). Intervention: Neoadjuvant pembrolizumab or NAC and RC. Outcome measurements and statistical analysis: Immune signatures and molecular subtyping (The Cancer Genome Atlas, consensus model, and genomic subtyping classifier [GSC]) were evaluated in relation to CR and PFS. Multivariable logistic regression analyses for CR were used, adjusting for gender and clinical T stage. Results and limitations: The Immune190 signature was significant for CR on multivariable logistic regression analyses (p = 0.02) in PURE-01, but not in the NAC cohort (p = 0.7). Hallmark signatures for interferon gamma (IFNγ; p = 0.004) and IFNα response (p = 0.006) were also associated with CR for PURE-01, but not for NAC (IFNγ: p = 0.9 and IFNα: p = 0.8). In PURE-01, 93% of patients with the highest Immune190 scores (>1st quartile) had 2-yr PFS versus 79% of those with lower scores; no difference was observed in NAC patients, as well as for the other hallmarks in both groups. The neuroendocrine-like subtype had the worst 2-yr PFS in all three subtyping models (33%) and the GSC claudin-low subtype had the best, with no recurrences in 2 yr. Basal subtypes (across classifications) with higher Immune190 scores showed 100% 2-yr PFS after pembrolizumab therapy (p = 0.04, compared with basal-Immune190 low). Statistical analyses are limited by the small number of events and short follow-up. Conclusions: Higher RNA-based immune signature scores were significantly associated with CR and numerically improved PFS outcomes after pembrolizumab, but not after NAC. These data emphasize that RNA profiling is a potential tool for personalizing neoadjuvant therapy selection. Patient summary: We used gene expression profiling to evaluate the association between immune gene expression and response to neoadjuvant immunotherapy, compared with standard chemotherapy, in patients with muscle-invasive bladder cancer (MIBC). We found a significant association between immune gene expression and response to pembrolizumab, but not chemotherapy. We conclude that gene expression profiling has the potential to guide personalized neoadjuvant therapy in MIBC. By using gene expression profiling of transurethral bladder tumor resection samples from patients with muscle-invasive bladder cancer (MIBC), we reported a significant association between pre-existing immune gene expression and response to neoadjuvant pembrolizumab, but not to neoadjuvant chemotherapy. Different outcomes were also obtained according to the molecular subtype. Gene expression profiling has the potential to guide personalized neoadjuvant therapy in MIBC.

Published
2020

3. Spherical power error evaluation and stereopsis by using holographic optotype tests

Author

Sabrina Ventrudo, Víctor Navarro-Fuster, Inmaculada Pascual, Renzo Colombo, Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía, Universidad de Alicante. Instituto Universitario de Física Aplicada a las Ciencias y las Tecnologías, Università degli Studi di Padova Dipartimento di Fisica e Astronomia 'Galileo Galilei', and Holografía y Procesado Óptico

Subjects
Spherical power, Visual acuity, Holography, Stereoscopy, 02 engineering and technology, 01 natural sciences, law.invention, Photopolymer, 010309 optics, Optics, law, 0103 physical sciences, medicine, Stereopsis, Electrical and Electronic Engineering, Dioptre, Óptica, Physics, business.industry, 021001 nanoscience & nanotechnology, Atomic and Molecular Physics, and Optics, Amplitude of accommodation, Electronic, Optical and Magnetic Materials, medicine.anatomical_structure, Human eye, medicine.symptom, 0210 nano-technology, business
Abstract

Two holographic optotypes have been designed and fabricated using polyvinyl alcohol/acrylamide photopolymer in order to measure visual acuity and stereopsis. One of them was a multivergence target for subjective measurements to determine the spherical refractive error of the human eye in the range −5 to +4 diopters (D) in a single step. The amplitude of accommodation is determined at the same time. The second one was a stereopsis test with an embossed picture to determine the degree of stereoscopic difficulties. Ministerio de Economía y Competitividad (Spain) (FIS2014-56100-C2-1-P and FIS2015-66570-P); Generalitat Valenciana (Spain) (PROMETEO II/2015/015).

Published
2017

4. A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy

Author

Patrizio Rigatti, Vincenzo Scattoni, Luigi F. Da Pozzo, Renzo Colombo, Ferruccio Fazio, Marco Roscigno, Francesco Montorsi, Claudio Fiorino, Roberto Bertini, Cesare Cozzarini, Angelo Bolognesi, A. Pasta, Roscigno, M, Cozzarini, C, Scattoni, V, Bertini, R, Da Pozzo, L, Pasta, A, Montorsi, F, Bolognesi, A, Fiorino, C, Colombo, R, Fazio, F, Rigatti, P, Roscigno, Marco, Cozzarini, Cesare, Scattoni, Vincenzo, Bertini, Roberto, Da Pozzo, Luigi, Pasta, Alessandra, Montorsi, Francesco, Bolognesi, Angelo, Fiorino, Claudio, Colombo, Renzo, Fazio, Ferruccio, and Rigatti, Patrizio

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Biopsy, Urinary Bladder, Urology, Salvage therapy, Anastomosis, Prostate cancer, Urethra, PSA Failure, medicine, Humans, Radiology, Nuclear Medicine and imaging, Survival analysis, Aged, Retrospective Studies, Salvage radiation therapy, Prostatectomy, Salvage Therapy, medicine.diagnostic_test, business.industry, Anastomosis, Surgical, Vesicourethral anastomosi, Prostatic Neoplasms, Radiotherapy Dosage, Hematology, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Surgery, Radiation therapy, Oncology, Multivariate Analysis, Radiotherapy, Adjuvant, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background and purpose: To investigate the usefulness of vesicourethral anastomotic biopsy (VUBx) in patients who are candidates for salvage radiotherapy (SalvRT) after radical prostatectomy (RRP). Material and methods: From 1992 to 2001, 98 patients with a PSA failure (PSAf) after RRP underwent SalvRT to the prostatic bed (median dose 70 Gy). In 50/98 patients the VUBx was positive, in 26 negative; 22 patients underwent salvRT without a prior VUBx. The prognostic impact on biochemical disease-free survival (bNEDs) of histologic confirmation of the local failure was evaluated retrospectively. Results: In the 40 patients with pre-RT PSA

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results